Navigation Links
Trius Appoints Paul Truex to Board of Directors
Date:6/1/2008

Industry veteran brings business development and transaction expertise

SAN DIEGO, June 2 /PRNewswire/ -- Trius Therapeutics, Inc. today announced the appointment of Paul Truex to its Board of Directors. Truex is the founder, President and CEO of Anthera Pharmaceuticals. Previously he served as President and CEO of Peninsula Pharmaceuticals where he raised over $81 million of institutional capital (including $21000000 from a key strategic partner) and negotiated both of Peninsula's product agreements with Shionogi & Co. Ltd. and Takeda Chemical Industries. Peninsula was acquired by Johnson & Johnson in 2005 for $245 million in an all cash transaction. Earlier in his career, Mr. Truex was Vice President of Commercial Development for Versicor (subsequently Vicuron which was acquired by Pfizer) where he directed early commercial efforts for infectious disease products and assisted with the company's successful IPO. Before Versicor he worked at Eli Lilly in various marketing and sales roles during the launch of three different products for the primary care physician market (Actos(R) Evista(R) and Humalog 75/25(R)).

"It is with great pleasure that we welcome Paul to the Trius Board," said David Kabakoff, Ph.D., Chairman of the Board of Trius. "His business development and product commercialization experience in anti-infectives fit very well with Trius' stage of development and strategy."

"I look forward to working closely with the Trius Board and management team to help build and realize value," said Truex. "Their lead clinical stage drug, TR-701, as well as their preclinical programs will provide the company with compelling business opportunities."

The addition of Truex to Trius' Board completes a transition following Trius' $30 million Series B financing completed in March. At that time, Risa Stack, Ph.D. of Kleiner Perkins joined the Board. Former board members Julia Brown and Takashi Kiyoizumi, M.D., Ph.D. have joined Trius' Business
'/>"/>

SOURCE Trius Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Pelikan Technologies Appoints Denny Ware to Board of Directors
2. MAP Pharmaceuticals Appoints Marco Rosa Vice President of Human Resources
3. Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
4. Nventa Appoints Gordon H. Busenbark to Board of Directors
5. Schering-Plough Appoints Janet M. Barth Vice President, Investor Relations
6. Informed Medical Communications Appoints New Chief Financial Officer
7. Orchid Cellmark Appoints Jeffrey S. Boschwitz as Vice President, North America Marketing & Sales
8. WuXi PharmaTech (NYSE: WX) Appoints Dr. Peng Wang as VP of Discovery Biology
9. Takedas Antibody Therapeutics Research Company, Takeda San Francisco, Inc. Appoints Mary Haak-Frendscho, Ph.D. as President and CSO
10. VentiRx Pharmaceuticals Appoints Dr. Elliott Grossbard to Board of Directors
11. Regenesis Biomedical Appoints Scientific Advisory Board Composed of Life Science and Electronics Experts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... how facets form and develop on platinum nanocubes ... nanocrystal design and reveal that a nearly 150 ... at the nanoscale. , Researchers with the U.S. ... (Berkeley Lab) used highly sophisticated transmission electron microscopes ... the physical mechanisms that control the evolution ...
(Date:8/22/2014)... 22, 2014 Ophthalmic drug delivery ... and challenging endeavors as the anatomy, physiology and ... to the foreign substances. Ocular drug delivery technologies ... medication and minimal use of needles; also it ... and provides specific targeting within the ocular globe. ...
(Date:8/22/2014)... 22, 2014 Research and Markets ... China Gel Permeation Chromatography (GPC) Industry Report 2014" ... and China Gel Permeation Chromatography (GPC) Industry Report is ... of the global gel permeation chromatography industry with a ... a basic overview of the industry including definitions, classifications, ...
(Date:8/22/2014)... August 22, 2014 The AMA is ... its members in Alaska that Alaska Governor Sean Parnell ... 15, further defining public use of Unmanned Aircraft Systems ... Force. House Bill 255states that it is, “An Act ... captured by an unmanned aircraft system.” It defines State ...
Breaking Biology Technology:Shaping the future of nanocrystals 2Shaping the future of nanocrystals 3Shaping the future of nanocrystals 4Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 4Global and China Gel Permeation Chromatography (GPC) Industry Report 2014 2State of Alaska Signs Unmanned Aircraft Systems Bill 2
... Sept. 6, 2011 The Immune Deficiency Foundation (IDF) ... continuing education (CE) course for  nurses. The goal of ... nurses by providing an educational update on primary immunodeficiency ... is the national patient organization dedicated to improving the ...
... 6, 2011 Auxilium Pharmaceuticals, Inc. (NASDAQ: ... safety update following 17 months of post-approval use in ... Dupuytren,s contracture patients with a palpable cord.  After approximately ... U.S., there was no clinically meaningful change in the ...
... Genprex, Inc., formerly known as Convergen LifeSciences, Inc., announced today ... will be branded as Oncoprex™ .   ... oncology sector in recognition of our advancing development programs.  We ... to unlock the unrealized potential of a growing list of ...
Cached Biology Technology:Immune Deficiency Foundation Launches Free Accredited Course for Nurses About Primary Immunodeficiency and Immunoglobulin Therapy 2Immune Deficiency Foundation Launches Free Accredited Course for Nurses About Primary Immunodeficiency and Immunoglobulin Therapy 3Auxilium Pharmaceuticals, Inc. Announces 17 Month XIAFLEX® Safety Update 2Auxilium Pharmaceuticals, Inc. Announces 17 Month XIAFLEX® Safety Update 3Auxilium Pharmaceuticals, Inc. Announces 17 Month XIAFLEX® Safety Update 4Genprex Announces New Branding 2
(Date:8/22/2014)... , August 22, 2014 ... ) has announced the addition of ... 2014-2018"  report to their offering.  ... ,Biometrics is a technology that helps ... on their physical or behavioral features. ...
(Date:8/22/2014)... RIVERSIDE, Calif. Thomson Reuters , a leading ... five researchers at the University of California, Riverside in ... brightest minds of our times." , To generate the ... (2002-2012) to identify researchers whose published work has had ... included among some 3,200 individuals who published the greatest ...
(Date:8/22/2014)... the 29th Annual International Papillomavirus Conference shows that ... combats three types of human papillomavirus, including the ... cancer. , When tested in several cultured human ... HPV-18 and HPV-11 cells, according to Louise T. ... the findings at the Seattle conference. The National ...
Breaking Biology News(10 mins):Biometrics Market in North America 2014-2018: Key Vendors are 3M Cogent, Cross Match, NEC and Safran SA 2Biometrics Market in North America 2014-2018: Key Vendors are 3M Cogent, Cross Match, NEC and Safran SA 35 UC Riverside scientists among world's most influential scientific minds 2
... Inc. (Nasdaq: AWRE ), a leading supplier of ... to discuss the company,s operating results for the fourth quarter ... 5:00 p.m. Eastern Time. CEO Michael Tzannes and CFO Rick ... webcast by Thomson and can be accessed on the Investor ...
... the potentially fatal hepatitis C virus has banked its ... inability to infect animals other than humans and chimpanzees ... animal model for the disease. But now, in a ... online issue of Nature , Rockefeller University scientists ...
... . , Lack of sleep is a ... the day poses a very real and dangerous problem. ... at McGill University demonstrates interestingly, that sleep-wake states are ... melanin-concentrating hormone (MCH) neurons and orexin (Orx) neurons, which ...
Cached Biology News:Aware Announces Q4 and FY2008 Earnings Conference Call 2Discovery could lead to a new animal model for hepatitis C 2What happens when we sleep 2
... Designed specifically for high efficiency ... Low toxicity reagent proven to ... range of cell types. Results ... 95% of target gene expression. ...
... measurements in an easy-to-use benchtop package. ... spectrometer (ESI-oa-TOF) concentrates the performance of ... which fits on your bench. The ... 10,000 FWHM and mass accuracy of ...
... The lower cost and reduced ... system make reference standard DNA analysis ... be used with any of SEQUENOM's ... High-Performance Genotyping (iPLEXTM Gold) , Gene ...
... jetSI-ENDO-FluoR is a tetramethylrhodamine-conjugated jetSI-ENDO ... at 580 nm), the powerful ... are used to determine the ... intracellular delivery and trafficking of ...
Biology Products: